These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 28751557)

  • 1. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
    Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
    Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
    Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
    Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
    Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
    Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
    Lim SL; Damnernsawad A; Shyamsunder P; Chng WJ; Han BC; Xu L; Pan J; Pravin DP; Alkan S; Tyner JW; Koeffler HP
    Haematologica; 2019 Jun; 104(6):1209-1220. PubMed ID: 30606790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 Jul; 30(14):3023-3035. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
    Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
    Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
    Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
    J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
    Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.